Skip to main content
Erschienen in: Reactions Weekly 1/2024

01.04.2024 | Case report

Ipilimumab/nivolumab

Various toxicitie

Erschienen in: Reactions Weekly | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is:
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Bell PT, et al. Anti-synthetase syndrome associated interstitial lung disease after combination dual immune checkpoint inhibition. Respirology Case Reports 11: 1-4, No. 4, Apr 2023. Available from: URL: 10.1002/rcr2.1115 Bell PT, et al. Anti-synthetase syndrome associated interstitial lung disease after combination dual immune checkpoint inhibition. Respirology Case Reports 11: 1-4, No. 4, Apr 2023. Available from: URL: 10.1002/rcr2.1115
Metadaten
Titel
Ipilimumab/nivolumab
Various toxicitie
Publikationsdatum
01.04.2024
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2024
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-024-56310-1

Weitere Artikel der Ausgabe 1/2024

Reactions Weekly 1/2024 Zur Ausgabe

Case report

Testosterone

Case report

Baricitinib

Case report

Epinephrine

Case report

Naproxen

Case report

Amiodarone

Case report

Imatinib